OSTEOCLAST ACTIVITY

摘要

The invention relates to medicaments and novel methods of treating metabolic bone diseases, and more particularly for treating or preventing Critical Illness Related Metabolic Bone Disease or of critical illness induced Osteopenia [ICD-10 M85.8, ICD-9 733.90, DiseasesDB 29870 or MeSH D001851] secondary to ICU Admission by sufficient autophagy inducing compound to inhibit or suppressing critical illness [MeSH Descriptor: C23.550.291.625] enhanced osteoclastogenesis or increased osteoclast differentiation. The disclosed therapeutic methods include administering of a autophagy activating compound to a mammal to: (1) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) maintain bone mass and/or bone quality or (5) inhibit bone resorption in particularly by inhibiting or reducing a process by which osteoclasts break down bone and release the minerals resulting in a transfer of calcium from bone fluid to the blood. The invention also provides methods for administering the autophagy activating compound to treat a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts.